Navigation Links
Dutasteride not a cost-effective way to prevent prostate cancer in some men
Date:2/8/2011

DALLAS Feb. 8, 2011 The popular drug dutasteride may not be a cost-effective way to prevent prostate cancer in men who are at elevated risk of developing the disease, according to findings by a UT Southwestern Medical Center researcher.

In a study available in the January issue of Cancer Prevention Research, investigators found that the medication, at an annual cost of $1,400, is impractical when compared to the marginal impact on survival and quality of life in at-risk groups. The drug is indicated for the treatment of enlarged prostates but also is widely prescribed for chemoprevention.

"Because prostate cancer is the most common cancer in men, the implications of this data are significant since there could be millions of men who would be eligible for anti-cancer drugs," said Dr. Yair Lotan, associate professor of urology at UT Southwestern. "Prior to instituting a chemoprevention strategy to a large population, the utility and cost need to be well understood. Whether a medication improves survival, how it affects quality of life, and what its financial implications will be are all critical issues. Because dutasteride typically is prescribed for the lifetime of the patient, and therefore taken daily for decades, the cost issue is particularly relevant."

Prior research has shown that dutasteride reduced the relative risk of prostate cancer over a four-year period by 22.8 percent, but questions have remained about its cost-effectiveness. The current study analyzed the lifetime health-related costs of the drug in patients at greater risk of developing prostate cancer and compared them to other factors, such as quality and length of life.

Dr. Lotan and his colleague, Dr. Robert Svatek of UT Health Science Center at San Antonio, used a Markov probability model to compare the lifetime cost of taking dutasteride with no therapy. They used data from a previous trial and studies that evaluated outcomes of patients with prostate cancer, including treatment-related complications to create the model. The primary outcome was measured in quality-adjusted life years (QALY), which takes into account both quality and quantity of life.

"The study found that dutasteride was not cost-effective for chemoprevention unless and until a strategy is developed for targeting very high-risk patients and the cost of the drug decreases," said Dr. Lotan. "For the average man, the drug provides minimal survival benefits, and the reduction on treatment-related complications does not compensate for the high costs of every man taking the drug for many years."


'/>"/>

Contact: Rachel Skei Donihoo
rachel.donihoo@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. European Urology: Editorial about REDUCE trial underlines value of dutasteride
2. Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment
3. Web-based questionnaire can be cost-effective tool for survey responses
4. Testing African couples for HIV is cost-effective prevention strategy
5. Wider statin use could be cost-effective preventive measure, Stanford study finds
6. Centralized health care more cost-effective, offers better access to preventive services
7. Trauma center care cost-effective
8. UNC physician authors editorial on cost-effectiveness study for colon cancer screening
9. Colorectal cancer screening in Canada is cost-effective
10. Antiviral therapy during compensated cirrhosis most cost-effective approach
11. Hospital Focus 5 Announces Contract with Connecticut Hospital to Improve Quality, Productivity and Cost-Effectiveness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Yisrayl Hawkins, Pastor ... that explains one of the most popular and least understood books in the Holy ... and puzzling descriptions that have baffled scholars for centuries. Many have tossed it off ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today ... Las Piedras, Puerto Rico , where ... Following a comprehensive ... minor structural damage, temporary loss of power and minimal ... completed, manufacturing operations have resumed, and the company expects ...
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare product ... training aide "cprCUBE" on Kickstarter. The device will educate ... cardiac arrests with better efficiency compared to the dated ... real-time feedback on efficacy of the compression for a ... has a goal to raise $5,000. ...
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
Breaking Medicine Technology: